Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003910 · ClinicalTrials.gov registry record · Phase 2
Methotrexate With or Without Cyclophosphamide in Treating Patients With Lymphocytic Leukemia
A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
- Terminated
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
NCT00003910: Clinical Trial Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
NCT00003910 is a Phase 2 study that was terminated before completion, run by Eastern Cooperative Oncology Group. The registered enrollment target is 59 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003910, a Phase 2 study, was terminated before completion, sponsored by Eastern Cooperative Oncology Group.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of methotrexate with or without cyclophosphamide in treating patients who have lymphocytic leukemia with neutropenia or anemia.
Primary Outcome
We will report the overall response rate below. Complete remission requires that all of the following be present for at least four weeks: The patient must have a normal CBC including neutrophil count \> 1500/mm3, lymphocyte count\< 4000/mm3, hemoglobin \> 11 g/dl, and platelet count \> 100,000/mm3. In addition, the patient must have a normal LGL count. A complete response will be attained if CD8+ cells were less than 760/mm³. A partial response will be defined as achievement of any one of the fo
Interventions
- DRUG Cyclophosphamide
- DRUG Prednisone
- DRUG Methotrexate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 1999-09-15 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
Why NCT00003910 stopped before completion
NCT00003910 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% lower).
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT00003910 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003910 about?
NCT00003910 is a clinical study titled "Methotrexate With or Without Cyclophosphamide in Treating Patients With Lymphocytic Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of methotrexate with or without cyclophosphamide in treating patients who have lymphocytic leukemia with neutropenia or anemia.
What is the current status of trial NCT00003910?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 1999-09-15. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00003910?
The interventions under investigation include: Cyclophosphamide (DRUG), Prednisone (DRUG), Methotrexate (DRUG).
Who is sponsoring clinical trial NCT00003910?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00003910's enrollment target sits among peer trials
59 1133rd of 2000 higher than 866 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI